Reduced left ventricular compliance and mechanical efficiency after prolonged inhibition of NO synthesis in conscious dogs.
Acute inhibition of NO synthesis decreases left ventricular (LV) work and external efficiency, but it is unknown whether compensatory mechanisms can limit the alterations in LV mechanoenergetics after prolonged NO deficiency. Eight chronically instrumented male mongrel dogs received 35 mg kg-1 day-1 of Nomega-nitro-L-arginine methyl ester orally for 10 days to inhibit NO synthesis. At spontaneous beating frequency, heart rate, coronary blood flow, peak LV pressure, end-diastolic LV pressure and the maximum derivative of LV pressure (dP/dtmax) were not significantly different vs. baseline, whereas LV end-diastolic diameter (32.5 +/- 1.0 vs. 37.6 +/- 1.4 mm) and LV stroke work (515 +/- 38 vs. 650 +/- 44 mmHg mm), were reduced (all P < 0.05). The slope of the LV end-systolic pressure-diameter relationship was increased at 10 days vs. baseline (13.9 +/- 1.0 vs. 9.6 +/- 0.9 mmHg mm-1, P < 0.05), while the end-diastolic LV diameter was smaller at matched LV end-diastolic pressures. At fixed heart rate (130 beats min-1), cardiac oxygen consumption was increased (12.2 +/- 1.5 vs. 9.9 +/- 1.0 ml min-1), and the ratio between stroke work and oxygen consumption was decreased by 33 +/-7 % (all P < 0.05) after NO inhibition. We conclude that sustained inhibition of NO synthesis in dogs causes a decrease in LV work despite an increased contractility, which is most probably due to reduced diastolic compliance and a decrease in external efficiency. Thus, prolonged NO deficiency is not compensated for on the level of LV mechanoenergetics in vivo.
Post
Heiner
H
Department of Physiology, New York Medical College, Valhalla, NY 10595, USA.
d'Agostino
Chiara
C
Lionetti
Vincenzo
V
Castellari
Michele
M
Kang
Elaine Y
EY
Altarejos
Martin
M
Xu
Xiaobin
X
Hintze
Thomas H
TH
Recchia
Fabio A
FA
D000818:Animals; D001794:Blood Pressure; D003187:Compliance; D003243:Consciousness; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006339:Heart Rate; D008297:Male; D009206:Myocardium / Q000378:metabolism; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology*
D004791:Enzyme Inhibitors; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester